For our cervical cancer vaccine we pursued the objective of inducing a strong immune response and protection that lasts. We are encouraged by a sustained enhanced antibody response we saw with an HPV vaccine formulated with our novel adjuvant.
Our strategy is to focus on women to try to prevent cervical cancer in the most cost effective way. We intend to seek licensure for a broad age range.